

Bangkok Chain Hospital Pcl (BCH TB) - HOLD

Siriporn Arunothai | Email: Siriporn.aru@thanachartsec.co.th

Earnings Preview

Weak-than-expected in 4Q25F earnings

- BCH to post 73% y-y earnings growth in 4Q25F.**
- This is likely to be slightly weaker than expected.**
- Key drivers are rising cash patients and low base effect.**
- We maintain HOLD on BCH.**

We expect BCH to report a normalized profit of Bt297m in 4Q25F, up 73% y-y but down 5% q-q, slightly below our previous expectation due to a Bt53m revenue reversal from high-cost care services under the Social Security Scheme (SSS). Looking ahead, we expect earnings to improve this year, but we maintain a HOLD rating given the likelihood that BCH will enter a capacity expansion phase in 2027, which could pressure earnings growth.

- We estimate that BCH will report a normalized profit of Bt297m for 4Q25F, up 73% y-y but down 5% q-q. This is likely to be slightly weaker than our previous expectation due to a Bt53m revenue reversal related to high-cost care services ($Rw \geq 2$), which will be booked in 4Q25.
- The y-y earnings growth is expected to be driven by rising revenue from cash patients and a low base effect from SSS revenue in 4Q24. The q-q earnings drop is expected due to falling revenue from SSS.
- Total revenue is estimated to grow by 8.6% y-y but decline by 1% q-q to Bt3bn in 4Q25. Revenue from cash patients is estimated to grow by 2% y-y and 1% q-q to Bt2bn. The Thailand–Cambodia cross-border issue caused Kasemrad International Hospital Aranyaprathet to be closed for two weeks in December 2025 and also negatively impacted fly-in Cambodian patients at other hospitals in Bangkok. Meanwhile, revenue from the SSS is estimated to grow by 16% y-y but decline by 5% q-q to Bt991m. The strong y-y growth in SSS revenue is mainly due to a lower revenue reversal from high-cost care services, which fell from Bt163m in 4Q24 to Bt53m in 4Q25. Note that BCH was required by the Social Security Office (SSO) to refund Bt53m in 4Q25 following a document review of high-cost care services provided before 2025.
- Gross margin is estimated at 26% in 4Q25, up from 22.8% in 4Q24 but down from 27.6% in 3Q25. EBIT margin is expected to be 13.1% in 4Q25, up from 7.8% in 4Q24 but down from 14.6% in 3Q25.
- Including 4Q25F earnings, we expect to see slightly downside risk to our earnings. Looking ahead to this year, we expect BCH's earnings to improve from last year, driven by rising revenue from cash patients and SSS patients, as well as margin expansion. However, we maintain our HOLD rating on BCH, as we expect it to enter a capacity expansion phase in 2027, which could pressure earnings growth.

Key Valuations


Y/E Dec (Bt m)	2024A	2025F	2026F	2027F
Revenue	11,725	11,984	12,617	14,217
Net profit	1,282	1,372	1,485	1,490
Norm net profit	1,221	1,337	1,485	1,490
Norm EPS (Bt)	0.5	0.5	0.6	0.6
Norm EPS gr (%)	(13.2)	9.5	11.1	0.3
Norm PE (x)	20.6	18.8	17.0	16.9
EV/EBITDA (x)	9.5	8.5	8.0	7.5
P/BV (x)	1.9	1.9	1.8	1.8
Div. yield (%)	4.0	4.1	4.4	4.4
ROE (%)	9.6	10.2	11.0	10.7
Net D/E (%)	(3.6)	(4.2)	(2.6)	(7.8)

Source: Thanachart estimates

Stock Data

Closing price (Bt)	10.1
Target price (Bt)	11.0
Market cap (US\$ m)	811.2
Avg daily turnover (US\$ m)	3.6
12M H/L price (Bt)	16.2/9.4

Price Performance



Source: Bloomberg

DISCLAIMER

General Disclaimers And Disclosures:

This report is prepared and issued by Thanachart Securities Public Company Limited (TNS) which is owned 99.97% by TMBThanachart Bank Public Company Limited (TTB) as a resource only for clients of TNS, TMBThanachart Bank Public Company Limited (TTB) and its group companies. Copyright © Thanachart Securities Public Company Limited. All rights reserved. The report may not be reproduced in whole or in part or delivered to other persons without our written consent.

This report is prepared by analysts who are employed by the research department of TNS. While the information is from sources believed to be reliable, neither the information nor the forecasts shall be taken as a representation or warranty for which TNS or TTB or its group companies or any of their employees incur any responsibility. This report is provided to you for informational purposes only and it is not, and is not to be construed as, an offer or an invitation to make an offer to sell or buy any securities. Neither TNS, TTB nor its group companies accept any liability whatsoever for any direct or consequential loss arising from any use of this report or its contents.

The information and opinions contained herein have been compiled or arrived at from sources believed reliable. However, TNS, TTB and its group companies make no representation or warranty, express or implied, as to their accuracy or completeness. Expressions of opinion herein are subject to change without notice. The use of any information, forecasts and opinions contained in this report shall be at the sole discretion and risk of the user.

TNS, TTB and its group companies perform and seek to perform business with companies covered in this report. TNS, TTB, its group companies, their employees and directors may have positions and financial interest in securities mentioned in this report. TNS, TTB or its group companies may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any entity mentioned in this report. Therefore, investors should be aware of conflict of interest that may affect the objectivity of this report.

Disclosure of Interest of Thanachart Securities

Investment Banking Relationship

Within the preceding 12 months, Thanachart Securities has lead-managed public offerings and/or secondary offerings (excluding straight bonds) of the securities of the following companies:

Note: Thanachart Securities Public Company Limited (TNS) acts as an underwriter of "Debentures of Charoen Pokphand Food Public Co. Ltd.(CPF) No. 1/2026 (B.E. 2569) tranche 1-3", therefore investors need to be aware that there could be conflicts of interest in this research.